Vaccine Technology

VEROVACCiNES novel vaccines are based on recombinant strains of the yeast Kluyveromyces lactis, which stably express one or more antigens. 

This novel class of vaccines has significant advantages over conventional animal vaccines.

HOW DOES THE TECHNOLOGY WORK?

VEROVACCiNES novel vaccines are based on recombinant strains of the yeast Kluyveromyces lactis, which stably express one or more antigens. 

VEROVACCiNES Podcast

Hear about the challenges to spin-off a start-up company and to find your place in the animal health field.

VEROVACCiNES Fermenter Installation

Installation of a new fermenter system, which enables us to:

  • speed up optimization of manufacturing (upstream processing)
  • generate quantitative and qualitative data for our K. lactis yeast system
  • produce vaccine material under highly controlled conditions

USPs

High efficacy

The antigen(s) are expressed in eukaryotic cells allowing protein modifications, the native expression of membrane proteins and the formation of Virus-Like Particles (VLP’s). This expression system is tailored for the generation of highly immunogenic subunit vaccines.

Non-infectious, highly immunogenic Virus Like Particles (VLPs) isolated from recombinant K. lactis yeast (Electron microscopic image courtesy of Dr. Dr. Gerd Hause, Martin-Luther University Halle-Wittenberg, Germany)